Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 47. More products

PAROXETINE HCL

13 general benefit · 11 not a benefit

Other products in the same Health Canada class (N06A, N06AB) — coverage varies; not interchangeable

  • Citalopram (Celexa): general benefit, Not a benefit
  • Escitalopram (Cipralex MELTZ): general benefit, Not a benefit
  • Fluoxetine (Prozac): general benefit, Not a benefit
  • Fluvoxamine (Luvox): general benefit
  • Sertraline (Zoloft): general benefit
  • Amitriptyline (Elavil): general benefit

17 more in the class list below

Apo-Paroxetine · DIN 02240908 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Paroxetine · DIN 02240908 Manufacturer: Apotex Inc.; listing date 2004-04-06 Health Canada: Marketed since 2003-10-24 · brand APO-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 20 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Paroxetine: Formulary list price $0.3250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64499 · Verify on the e-Formulary ↗ (DIN 02240908)

Source record
DIN 02240908: Apo-Paroxetine Raw flags: sec3=Y Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3250; ministry $0.3250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240908 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64499
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250 Auro-Paroxetine · DIN 02383284 · $0.3250 Co Paroxetine · DIN 02262754 · $0.3250 Jamp Paroxetine Tablets · DIN 02507781 · $0.3250 Jamp-Paroxetine · DIN 02368870 · $0.3250 M-Paroxetine · DIN 02467410 · $0.3250 Mar-Paroxetine · DIN 02411954 · $0.3250 Mint-Paroxetine · DIN 02421380 · $0.3250 NRA-Paroxetine · DIN 02479761 · $0.3250 PMS-Paroxetine · DIN 02247751 · $0.3250 Paroxetine · DIN 02282852 · $0.3250 Paroxetine · DIN 02388235 · $0.3250 Paxil · DIN 01940481 · $0.3250 Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250 Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: resolved shortage (ended 2021-04-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240908
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Paroxetine · DIN 02383284 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Paroxetine · DIN 02383284 Manufacturer: Auro Pharma Inc.; listing date 2012-09-28 Health Canada: Marketed since 2012-07-24 · brand AURO-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Paroxetine: Formulary list price $0.3250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86904 · Verify on the e-Formulary ↗ (DIN 02383284)

Source record
DIN 02383284: Auro-Paroxetine Raw flags: sec3=Y Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id AUR Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3250; ministry $0.3250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02383284 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86904
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250 Apo-Paroxetine · DIN 02240908 · $0.3250 Co Paroxetine · DIN 02262754 · $0.3250 Jamp Paroxetine Tablets · DIN 02507781 · $0.3250 Jamp-Paroxetine · DIN 02368870 · $0.3250 M-Paroxetine · DIN 02467410 · $0.3250 Mar-Paroxetine · DIN 02411954 · $0.3250 Mint-Paroxetine · DIN 02421380 · $0.3250 NRA-Paroxetine · DIN 02479761 · $0.3250 PMS-Paroxetine · DIN 02247751 · $0.3250 Paroxetine · DIN 02282852 · $0.3250 Paroxetine · DIN 02388235 · $0.3250 Paxil · DIN 01940481 · $0.3250 Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250 Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: resolved shortage (ended 2024-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02383284
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Paroxetine Tablets · DIN 02507781 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Paroxetine Tablets · DIN 02507781 Manufacturer: Jamp Pharma Corporation; listing date 2022-02-28 Health Canada: Marketed since 2022-01-03 · brand JAMP PAROXETINE TABLETS · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 20 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Paroxetine Tablets: Formulary list price $0.3250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99718 · Verify on the e-Formulary ↗ (DIN 02507781)

Source record
DIN 02507781: Jamp Paroxetine Tablets Raw flags: sec3=Y Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id JPC Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3250; ministry $0.3250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02507781 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99718
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250 Apo-Paroxetine · DIN 02240908 · $0.3250 Auro-Paroxetine · DIN 02383284 · $0.3250 Co Paroxetine · DIN 02262754 · $0.3250 Jamp-Paroxetine · DIN 02368870 · $0.3250 M-Paroxetine · DIN 02467410 · $0.3250 Mar-Paroxetine · DIN 02411954 · $0.3250 Mint-Paroxetine · DIN 02421380 · $0.3250 NRA-Paroxetine · DIN 02479761 · $0.3250 PMS-Paroxetine · DIN 02247751 · $0.3250 Paroxetine · DIN 02282852 · $0.3250 Paroxetine · DIN 02388235 · $0.3250 Paxil · DIN 01940481 · $0.3250 Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250 Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02507781
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Paroxetine · DIN 02467410 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Paroxetine · DIN 02467410 Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29 Health Canada: Marketed since 2018-03-07 · brand M-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Paroxetine: Formulary list price $0.3250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95579 · Verify on the e-Formulary ↗ (DIN 02467410)

Source record
DIN 02467410: M-Paroxetine Raw flags: sec3=Y Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id MAT Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3250; ministry $0.3250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467410 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95579
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250 Apo-Paroxetine · DIN 02240908 · $0.3250 Auro-Paroxetine · DIN 02383284 · $0.3250 Co Paroxetine · DIN 02262754 · $0.3250 Jamp Paroxetine Tablets · DIN 02507781 · $0.3250 Jamp-Paroxetine · DIN 02368870 · $0.3250 Mar-Paroxetine · DIN 02411954 · $0.3250 Mint-Paroxetine · DIN 02421380 · $0.3250 NRA-Paroxetine · DIN 02479761 · $0.3250 PMS-Paroxetine · DIN 02247751 · $0.3250 Paroxetine · DIN 02282852 · $0.3250 Paroxetine · DIN 02388235 · $0.3250 Paxil · DIN 01940481 · $0.3250 Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250 Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02467410
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Paroxetine · DIN 02411954 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Paroxetine · DIN 02411954 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-01-03 Health Canada: Marketed since 2014-06-24 · brand MAR-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Paroxetine: Formulary list price $0.3250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89652 · Verify on the e-Formulary ↗ (DIN 02411954)

Source record
DIN 02411954: Mar-Paroxetine Raw flags: sec3=Y Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id MAR Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3250; ministry $0.3250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02411954 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89652
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250 Apo-Paroxetine · DIN 02240908 · $0.3250 Auro-Paroxetine · DIN 02383284 · $0.3250 Co Paroxetine · DIN 02262754 · $0.3250 Jamp Paroxetine Tablets · DIN 02507781 · $0.3250 Jamp-Paroxetine · DIN 02368870 · $0.3250 M-Paroxetine · DIN 02467410 · $0.3250 Mint-Paroxetine · DIN 02421380 · $0.3250 NRA-Paroxetine · DIN 02479761 · $0.3250 PMS-Paroxetine · DIN 02247751 · $0.3250 Paroxetine · DIN 02282852 · $0.3250 Paroxetine · DIN 02388235 · $0.3250 Paxil · DIN 01940481 · $0.3250 Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250 Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02411954
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Paroxetine · DIN 02421380 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Paroxetine · DIN 02421380 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-05-29 Health Canada: Marketed since 2014-03-17 · brand MINT-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Paroxetine: Formulary list price $0.3250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90601 · Verify on the e-Formulary ↗ (DIN 02421380)

Source record
DIN 02421380: Mint-Paroxetine Raw flags: sec3=Y Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id MIN Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3250; ministry $0.3250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02421380 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90601
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250 Apo-Paroxetine · DIN 02240908 · $0.3250 Auro-Paroxetine · DIN 02383284 · $0.3250 Co Paroxetine · DIN 02262754 · $0.3250 Jamp Paroxetine Tablets · DIN 02507781 · $0.3250 Jamp-Paroxetine · DIN 02368870 · $0.3250 M-Paroxetine · DIN 02467410 · $0.3250 Mar-Paroxetine · DIN 02411954 · $0.3250 NRA-Paroxetine · DIN 02479761 · $0.3250 PMS-Paroxetine · DIN 02247751 · $0.3250 Paroxetine · DIN 02282852 · $0.3250 Paroxetine · DIN 02388235 · $0.3250 Paxil · DIN 01940481 · $0.3250 Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250 Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: resolved shortage (ended 2018-03-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02421380
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Paroxetine · DIN 02479761 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Paroxetine · DIN 02479761 Manufacturer: Nora Pharma; listing date 2020-07-31 Health Canada: Marketed since 2018-12-10 · brand NRA-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Paroxetine: Formulary list price $0.3250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97011 · Verify on the e-Formulary ↗ (DIN 02479761)

Source record
DIN 02479761: NRA-Paroxetine Raw flags: sec3=Y Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id NRA Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3250; ministry $0.3250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479761 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97011
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250 Apo-Paroxetine · DIN 02240908 · $0.3250 Auro-Paroxetine · DIN 02383284 · $0.3250 Co Paroxetine · DIN 02262754 · $0.3250 Jamp Paroxetine Tablets · DIN 02507781 · $0.3250 Jamp-Paroxetine · DIN 02368870 · $0.3250 M-Paroxetine · DIN 02467410 · $0.3250 Mar-Paroxetine · DIN 02411954 · $0.3250 Mint-Paroxetine · DIN 02421380 · $0.3250 PMS-Paroxetine · DIN 02247751 · $0.3250 Paroxetine · DIN 02282852 · $0.3250 Paroxetine · DIN 02388235 · $0.3250 Paxil · DIN 01940481 · $0.3250 Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250 Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02479761
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Paroxetine · DIN 02247751 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Paroxetine · DIN 02247751 Manufacturer: Pharmascience Inc.; listing date 2004-04-06 Health Canada: Marketed since 2003-10-29 · brand PMS-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 20 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Paroxetine: Formulary list price $0.3250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72043 · Verify on the e-Formulary ↗ (DIN 02247751)

Source record
DIN 02247751: PMS-Paroxetine Raw flags: sec3=Y Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id PMS Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3250; ministry $0.3250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247751 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72043
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250 Apo-Paroxetine · DIN 02240908 · $0.3250 Auro-Paroxetine · DIN 02383284 · $0.3250 Co Paroxetine · DIN 02262754 · $0.3250 Jamp Paroxetine Tablets · DIN 02507781 · $0.3250 Jamp-Paroxetine · DIN 02368870 · $0.3250 M-Paroxetine · DIN 02467410 · $0.3250 Mar-Paroxetine · DIN 02411954 · $0.3250 Mint-Paroxetine · DIN 02421380 · $0.3250 NRA-Paroxetine · DIN 02479761 · $0.3250 Paroxetine · DIN 02282852 · $0.3250 Paroxetine · DIN 02388235 · $0.3250 Paxil · DIN 01940481 · $0.3250 Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250 Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: resolved shortage (ended 2024-02-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247751
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Paroxetine · DIN 02282852 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Paroxetine · DIN 02282852 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2021-09-27 · brand PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Paroxetine: Formulary list price $0.3250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76847 · Verify on the e-Formulary ↗ (DIN 02282852)

Source record
DIN 02282852: Paroxetine Raw flags: sec3=Y Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id SAI Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3250; ministry $0.3250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02282852 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76847
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250 Apo-Paroxetine · DIN 02240908 · $0.3250 Auro-Paroxetine · DIN 02383284 · $0.3250 Co Paroxetine · DIN 02262754 · $0.3250 Jamp Paroxetine Tablets · DIN 02507781 · $0.3250 Jamp-Paroxetine · DIN 02368870 · $0.3250 M-Paroxetine · DIN 02467410 · $0.3250 Mar-Paroxetine · DIN 02411954 · $0.3250 Mint-Paroxetine · DIN 02421380 · $0.3250 NRA-Paroxetine · DIN 02479761 · $0.3250 PMS-Paroxetine · DIN 02247751 · $0.3250 Paroxetine · DIN 02388235 · $0.3250 Paxil · DIN 01940481 · $0.3250 Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250 Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: resolved shortage (ended 2021-09-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02282852
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Paroxetine · DIN 02388235 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Paroxetine · DIN 02388235 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-12-18 Health Canada: Marketed since 2016-02-09 · brand PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Paroxetine: Formulary list price $0.3250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87378 · Verify on the e-Formulary ↗ (DIN 02388235)

Source record
DIN 02388235: Paroxetine Raw flags: sec3=Y Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id SIV Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3250; ministry $0.3250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388235 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87378
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250 Apo-Paroxetine · DIN 02240908 · $0.3250 Auro-Paroxetine · DIN 02383284 · $0.3250 Co Paroxetine · DIN 02262754 · $0.3250 Jamp Paroxetine Tablets · DIN 02507781 · $0.3250 Jamp-Paroxetine · DIN 02368870 · $0.3250 M-Paroxetine · DIN 02467410 · $0.3250 Mar-Paroxetine · DIN 02411954 · $0.3250 Mint-Paroxetine · DIN 02421380 · $0.3250 NRA-Paroxetine · DIN 02479761 · $0.3250 PMS-Paroxetine · DIN 02247751 · $0.3250 Paroxetine · DIN 02282852 · $0.3250 Paxil · DIN 01940481 · $0.3250 Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250 Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: discontinued (2019-07-19, reported by SIVEM PHARMACEUTICALS ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388235
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Paxil · DIN 01940481 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Paxil (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Paxil · DIN 01940481 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Health Canada: Marketed since 2002-09-13 · brand PAXIL TAB 20MG · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 20 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.3250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14007 · Verify on the e-Formulary ↗ (DIN 01940481)

Source record
DIN 01940481: Paxil Raw flags: sec3=Y Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id GSK Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $2.5496; ministry $0.3250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01940481 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14007
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250 Apo-Paroxetine · DIN 02240908 · $0.3250 Auro-Paroxetine · DIN 02383284 · $0.3250 Co Paroxetine · DIN 02262754 · $0.3250 Jamp Paroxetine Tablets · DIN 02507781 · $0.3250 Jamp-Paroxetine · DIN 02368870 · $0.3250 M-Paroxetine · DIN 02467410 · $0.3250 Mar-Paroxetine · DIN 02411954 · $0.3250 Mint-Paroxetine · DIN 02421380 · $0.3250 NRA-Paroxetine · DIN 02479761 · $0.3250 PMS-Paroxetine · DIN 02247751 · $0.3250 Paroxetine · DIN 02282852 · $0.3250 Paroxetine · DIN 02388235 · $0.3250 Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250 Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: active shortage (reported 2026-04-30, estimated to end 2026-12-18, last updated 2026-06-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01940481
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Paroxetine · DIN 02248557 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Paroxetine · DIN 02248557 Manufacturer: Teva Canada Limited; listing date 2004-04-06 Health Canada: Marketed since 2024-02-15 · brand TEVA-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE ACETONE SOLVATE) 20 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Paroxetine: Formulary list price $0.3250/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3250 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72912 · Verify on the e-Formulary ↗ (DIN 02248557)

Source record
DIN 02248557: Teva-Paroxetine Raw flags: sec3=Y Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id TEV Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3250; ministry $0.3250 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248557 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72912
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250 Apo-Paroxetine · DIN 02240908 · $0.3250 Auro-Paroxetine · DIN 02383284 · $0.3250 Co Paroxetine · DIN 02262754 · $0.3250 Jamp Paroxetine Tablets · DIN 02507781 · $0.3250 Jamp-Paroxetine · DIN 02368870 · $0.3250 M-Paroxetine · DIN 02467410 · $0.3250 Mar-Paroxetine · DIN 02411954 · $0.3250 Mint-Paroxetine · DIN 02421380 · $0.3250 NRA-Paroxetine · DIN 02479761 · $0.3250 PMS-Paroxetine · DIN 02247751 · $0.3250 Paroxetine · DIN 02282852 · $0.3250 Paroxetine · DIN 02388235 · $0.3250 Paxil · DIN 01940481 · $0.3250 Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Shortage status: Reversed (report reversed by the reporter); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248557
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Paroxetine · DIN 02240909 · 30mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Paroxetine · DIN 02240909 Manufacturer: Apotex Inc.; listing date 2004-04-06 Health Canada: Marketed since 2003-10-24 · brand APO-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 30 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Paroxetine: Formulary list price $0.3453/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3453 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64500 · Verify on the e-Formulary ↗ (DIN 02240909)

Source record
DIN 02240909: Apo-Paroxetine Raw flags: sec3=Y Item: 281604079; group id 467; item number 1177; lccId None; manufacturer id APX Source form: Tab; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $0.3453; ministry $0.3453 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240909 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64500
Interchangeable products
AG-Paroxetine · DIN 02475553 · $0.3453 Auro-Paroxetine · DIN 02383292 · $0.3453 Jamp Paroxetine Tablets · DIN 02507803 · $0.3453 Jamp-Paroxetine · DIN 02368889 · $0.3453 M-Paroxetine · DIN 02467429 · $0.3453 Mar-Paroxetine · DIN 02411962 · $0.3453 Mint-Paroxetine · DIN 02421399 · $0.3453 NRA-Paroxetine · DIN 02479788 · $0.3453 PMS-Paroxetine · DIN 02247752 · $0.3453 Paroxetine · DIN 02282860 · $0.3453 Paroxetine · DIN 02388243 · $0.3453 Paxil · DIN 01940473 · $0.3453 Sandoz Paroxetine Tablets · DIN 02431793 · $0.3453 Teva-Paroxetine · DIN 02248558 · $0.3453
Shortage status: resolved shortage (ended 2023-10-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240909
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Paroxetine · DIN 02240907 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Paroxetine · DIN 02240907 Manufacturer: Apotex Inc.; listing date 2007-06-06 Health Canada: Marketed since 2003-10-24 · brand APO-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64498 · Verify on the e-Formulary ↗ (DIN 02240907)

Source record
DIN 02240907: Apo-Paroxetine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0430; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240907 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64498
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded Auro-Paroxetine · DIN 02383276 · not recorded Co Paroxetine · DIN 02262746 · not recorded Jamp Paroxetine Tablets · DIN 02507773 · not recorded Jamp-Paroxetine · DIN 02368862 · not recorded M-Paroxetine · DIN 02467402 · not recorded Mar-Paroxetine · DIN 02411946 · not recorded Mint-Paroxetine · DIN 02421372 · not recorded NRA-Paroxetine · DIN 02479753 · not recorded PMS-Paroxetine · DIN 02247750 · not recorded Paroxetine · DIN 02282844 · not recorded Paroxetine · DIN 02388227 · not recorded Paxil · DIN 02027887 · not recorded Sandoz Paroxetine Tablets · DIN 02431777 · not recorded Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: resolved shortage (ended 2023-10-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240907
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Paroxetine · DIN 02383276 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Paroxetine · DIN 02383276 Manufacturer: Auro Pharma Inc.; listing date 2012-12-21 Health Canada: Marketed since 2012-07-24 · brand AURO-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86903 · Verify on the e-Formulary ↗ (DIN 02383276)

Source record
DIN 02383276: Auro-Paroxetine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id AUR Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0430; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02383276 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86903
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded Apo-Paroxetine · DIN 02240907 · not recorded Co Paroxetine · DIN 02262746 · not recorded Jamp Paroxetine Tablets · DIN 02507773 · not recorded Jamp-Paroxetine · DIN 02368862 · not recorded M-Paroxetine · DIN 02467402 · not recorded Mar-Paroxetine · DIN 02411946 · not recorded Mint-Paroxetine · DIN 02421372 · not recorded NRA-Paroxetine · DIN 02479753 · not recorded PMS-Paroxetine · DIN 02247750 · not recorded Paroxetine · DIN 02282844 · not recorded Paroxetine · DIN 02388227 · not recorded Paxil · DIN 02027887 · not recorded Sandoz Paroxetine Tablets · DIN 02431777 · not recorded Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: resolved shortage (ended 2022-10-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02383276
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Paroxetine Tablets · DIN 02507773 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Paroxetine Tablets · DIN 02507773 Manufacturer: Jamp Pharma Corporation; listing date 2021-07-30 Health Canada: Marketed since 2022-01-03 · brand JAMP PAROXETINE TABLETS · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 10 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99717 · Verify on the e-Formulary ↗ (DIN 02507773)

Source record
DIN 02507773: Jamp Paroxetine Tablets Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0430; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02507773 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99717
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded Apo-Paroxetine · DIN 02240907 · not recorded Auro-Paroxetine · DIN 02383276 · not recorded Co Paroxetine · DIN 02262746 · not recorded Jamp-Paroxetine · DIN 02368862 · not recorded M-Paroxetine · DIN 02467402 · not recorded Mar-Paroxetine · DIN 02411946 · not recorded Mint-Paroxetine · DIN 02421372 · not recorded NRA-Paroxetine · DIN 02479753 · not recorded PMS-Paroxetine · DIN 02247750 · not recorded Paroxetine · DIN 02282844 · not recorded Paroxetine · DIN 02388227 · not recorded Paxil · DIN 02027887 · not recorded Sandoz Paroxetine Tablets · DIN 02431777 · not recorded Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02507773
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Paroxetine · DIN 02467402 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Paroxetine · DIN 02467402 Manufacturer: Mantra Pharma Inc.; listing date 2021-11-30 Health Canada: Marketed since 2018-03-07 · brand M-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95578 · Verify on the e-Formulary ↗ (DIN 02467402)

Source record
DIN 02467402: M-Paroxetine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id MAT Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0430; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467402 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95578
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded Apo-Paroxetine · DIN 02240907 · not recorded Auro-Paroxetine · DIN 02383276 · not recorded Co Paroxetine · DIN 02262746 · not recorded Jamp Paroxetine Tablets · DIN 02507773 · not recorded Jamp-Paroxetine · DIN 02368862 · not recorded Mar-Paroxetine · DIN 02411946 · not recorded Mint-Paroxetine · DIN 02421372 · not recorded NRA-Paroxetine · DIN 02479753 · not recorded PMS-Paroxetine · DIN 02247750 · not recorded Paroxetine · DIN 02282844 · not recorded Paroxetine · DIN 02388227 · not recorded Paxil · DIN 02027887 · not recorded Sandoz Paroxetine Tablets · DIN 02431777 · not recorded Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02467402
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Paroxetine · DIN 02411946 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Paroxetine · DIN 02411946 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-01-03 Health Canada: Marketed since 2014-06-24 · brand MAR-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89654 · Verify on the e-Formulary ↗ (DIN 02411946)

Source record
DIN 02411946: Mar-Paroxetine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id MAR Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0430; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02411946 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89654
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded Apo-Paroxetine · DIN 02240907 · not recorded Auro-Paroxetine · DIN 02383276 · not recorded Co Paroxetine · DIN 02262746 · not recorded Jamp Paroxetine Tablets · DIN 02507773 · not recorded Jamp-Paroxetine · DIN 02368862 · not recorded M-Paroxetine · DIN 02467402 · not recorded Mint-Paroxetine · DIN 02421372 · not recorded NRA-Paroxetine · DIN 02479753 · not recorded PMS-Paroxetine · DIN 02247750 · not recorded Paroxetine · DIN 02282844 · not recorded Paroxetine · DIN 02388227 · not recorded Paxil · DIN 02027887 · not recorded Sandoz Paroxetine Tablets · DIN 02431777 · not recorded Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02411946
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Paroxetine · DIN 02421372 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Paroxetine · DIN 02421372 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-05-29 Health Canada: Marketed since 2014-03-17 · brand MINT-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90600 · Verify on the e-Formulary ↗ (DIN 02421372)

Source record
DIN 02421372: Mint-Paroxetine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id MIN Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0430; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02421372 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90600
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded Apo-Paroxetine · DIN 02240907 · not recorded Auro-Paroxetine · DIN 02383276 · not recorded Co Paroxetine · DIN 02262746 · not recorded Jamp Paroxetine Tablets · DIN 02507773 · not recorded Jamp-Paroxetine · DIN 02368862 · not recorded M-Paroxetine · DIN 02467402 · not recorded Mar-Paroxetine · DIN 02411946 · not recorded NRA-Paroxetine · DIN 02479753 · not recorded PMS-Paroxetine · DIN 02247750 · not recorded Paroxetine · DIN 02282844 · not recorded Paroxetine · DIN 02388227 · not recorded Paxil · DIN 02027887 · not recorded Sandoz Paroxetine Tablets · DIN 02431777 · not recorded Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: resolved shortage (ended 2018-04-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02421372
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Paroxetine · DIN 02479753 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
NRA-Paroxetine · DIN 02479753 Manufacturer: Nora Pharma; listing date 2020-07-31 Health Canada: Marketed since 2018-12-10 · brand NRA-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97010 · Verify on the e-Formulary ↗ (DIN 02479753)

Source record
DIN 02479753: NRA-Paroxetine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id NRA Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0430; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479753 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97010
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded Apo-Paroxetine · DIN 02240907 · not recorded Auro-Paroxetine · DIN 02383276 · not recorded Co Paroxetine · DIN 02262746 · not recorded Jamp Paroxetine Tablets · DIN 02507773 · not recorded Jamp-Paroxetine · DIN 02368862 · not recorded M-Paroxetine · DIN 02467402 · not recorded Mar-Paroxetine · DIN 02411946 · not recorded Mint-Paroxetine · DIN 02421372 · not recorded PMS-Paroxetine · DIN 02247750 · not recorded Paroxetine · DIN 02282844 · not recorded Paroxetine · DIN 02388227 · not recorded Paxil · DIN 02027887 · not recorded Sandoz Paroxetine Tablets · DIN 02431777 · not recorded Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02479753
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Paroxetine · DIN 02247750 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Paroxetine · DIN 02247750 Manufacturer: Pharmascience Inc.; listing date 2007-06-06 Health Canada: Marketed since 2018-09-05 · brand PMS-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 10 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72042 · Verify on the e-Formulary ↗ (DIN 02247750)

Source record
DIN 02247750: PMS-Paroxetine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0430; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247750 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72042
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded Apo-Paroxetine · DIN 02240907 · not recorded Auro-Paroxetine · DIN 02383276 · not recorded Co Paroxetine · DIN 02262746 · not recorded Jamp Paroxetine Tablets · DIN 02507773 · not recorded Jamp-Paroxetine · DIN 02368862 · not recorded M-Paroxetine · DIN 02467402 · not recorded Mar-Paroxetine · DIN 02411946 · not recorded Mint-Paroxetine · DIN 02421372 · not recorded NRA-Paroxetine · DIN 02479753 · not recorded Paroxetine · DIN 02282844 · not recorded Paroxetine · DIN 02388227 · not recorded Paxil · DIN 02027887 · not recorded Sandoz Paroxetine Tablets · DIN 02431777 · not recorded Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: resolved shortage (ended 2026-08-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247750
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Paroxetine · DIN 02282844 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Paroxetine · DIN 02282844 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2021-09-27 · brand PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76846 · Verify on the e-Formulary ↗ (DIN 02282844)

Source record
DIN 02282844: Paroxetine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id SAI Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0430; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02282844 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76846
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded Apo-Paroxetine · DIN 02240907 · not recorded Auro-Paroxetine · DIN 02383276 · not recorded Co Paroxetine · DIN 02262746 · not recorded Jamp Paroxetine Tablets · DIN 02507773 · not recorded Jamp-Paroxetine · DIN 02368862 · not recorded M-Paroxetine · DIN 02467402 · not recorded Mar-Paroxetine · DIN 02411946 · not recorded Mint-Paroxetine · DIN 02421372 · not recorded NRA-Paroxetine · DIN 02479753 · not recorded PMS-Paroxetine · DIN 02247750 · not recorded Paroxetine · DIN 02388227 · not recorded Paxil · DIN 02027887 · not recorded Sandoz Paroxetine Tablets · DIN 02431777 · not recorded Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: resolved shortage (ended 2021-09-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02282844
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Paroxetine · DIN 02388227 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Paroxetine · DIN 02388227 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-12-18 Health Canada: Marketed since 2016-02-09 · brand PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87377 · Verify on the e-Formulary ↗ (DIN 02388227)

Source record
DIN 02388227: Paroxetine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id SIV Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0430; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388227 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87377
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded Apo-Paroxetine · DIN 02240907 · not recorded Auro-Paroxetine · DIN 02383276 · not recorded Co Paroxetine · DIN 02262746 · not recorded Jamp Paroxetine Tablets · DIN 02507773 · not recorded Jamp-Paroxetine · DIN 02368862 · not recorded M-Paroxetine · DIN 02467402 · not recorded Mar-Paroxetine · DIN 02411946 · not recorded Mint-Paroxetine · DIN 02421372 · not recorded NRA-Paroxetine · DIN 02479753 · not recorded PMS-Paroxetine · DIN 02247750 · not recorded Paroxetine · DIN 02282844 · not recorded Paxil · DIN 02027887 · not recorded Sandoz Paroxetine Tablets · DIN 02431777 · not recorded Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388227
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Paroxetine · DIN 02248556 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Paroxetine · DIN 02248556 Manufacturer: Teva Canada Limited; listing date 2007-06-06 Health Canada: Marketed since 2024-02-15 · brand TEVA-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE ACETONE SOLVATE) 10 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72911 · Verify on the e-Formulary ↗ (DIN 02248556)

Source record
DIN 02248556: Teva-Paroxetine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0430; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248556 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72911
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded Apo-Paroxetine · DIN 02240907 · not recorded Auro-Paroxetine · DIN 02383276 · not recorded Co Paroxetine · DIN 02262746 · not recorded Jamp Paroxetine Tablets · DIN 02507773 · not recorded Jamp-Paroxetine · DIN 02368862 · not recorded M-Paroxetine · DIN 02467402 · not recorded Mar-Paroxetine · DIN 02411946 · not recorded Mint-Paroxetine · DIN 02421372 · not recorded NRA-Paroxetine · DIN 02479753 · not recorded PMS-Paroxetine · DIN 02247750 · not recorded Paroxetine · DIN 02282844 · not recorded Paroxetine · DIN 02388227 · not recorded Paxil · DIN 02027887 · not recorded Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Shortage status: resolved shortage (ended 2026-06-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248556
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

SERTRALINE HCL

· 49 products · General benefit · strengths: 25mg, 50mg, 100mg · Cap

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS PAXIL (paroxetine hydrochloride) is indicated in adults for the symptomatic treatment of:  Major Depressive Disorder (MDD)  Obsessive-Compulsive Disorder (OCD)  Panic Disorder (with or without agoraphobia)  Social Phobia (Social Anxiety Disorder)  Generalized Anxiety Disorder (GAD)  Posttraumatic Stress Disorder (PTSD) Long-Term Use of PAXIL: Clinical trials have provided evidence that continuation treatment with PAXIL in patients with moderate to moderately severe depressive disorder is effective for at least 6 months (see 14.1 Trial Design by indication, Major Depressive Disorder). The effectiveness of PAXIL in long-term use (i.e. more than 8 weeks for GAD and 12 weeks for other indications) has not yet been established in controlled trials for OCD, panic disorder, social phobia (social anxiety disorder), generalized anxiety disorder and posttraumatic stress disorder. Therefore, the health professional who elects to use PAXIL for extended periods in these indications should periodically re-evaluate the long-term usefulness of the drug for individual patients (see 4.1 Dosing Considerations). 1.1 Pediatrics Pediatrics (< 18 yea… https://pdf.hres.ca/dpd_pm/00067494.PDF PM date: May 4, 1993 Source product: PAXIL TAB 20MG; DIN 01940481; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Paroxetine · DIN 02388235 Shortage status: discontinued (2019-07-19, reported by SIVEM PHARMACEUTICALS ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388235

Check this DIN again

Paxil · DIN 01940481 Shortage status: active shortage (reported 2026-04-30, estimated to end 2026-12-18, last updated 2026-06-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01940481

Check this DIN again

Other review policies

For Apo-Paroxetine, Auro-Paroxetine, Jamp Paroxetine Tablets, M-Paroxetine, Mar-Paroxetine, Mint-Paroxetine, NRA-Paroxetine, PMS-Paroxetine, Paroxetine, Teva-Paroxetine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026